Chairman and CEO of Ignyta, Inc. (NASDAQ:RXDX); Managing Partner of City Hill Ventures, LLC; former Chairman and CEO of Eclipse Therapeutics, Inc., acquired by Bionomics (ASX:BNO); former President, CEO and Director of Halozyme Therapeutics, Inc. (NASDAQ:HALO).
FAUAD HASAN, MS, MBA
Chief Executive Officer, Co-Founder, Director
17 years biotech experience in the areas of process development, manufacturing, program management and business development. Served as the strategic and technical lead for neurotoxin programs at Allergan, which include next generation neurotoxin molecules. Formerly at Regeneron and Baxter.
ALEXEY KONOV, Ph.D
Serves as CEO and Partner of RBV Capital; Formerly Director of Business Development and Executive Director at Bioprocess Group, LLC; Served on board for Retrosense Therapeutics (acquired by Allergan). Education: University Louis Pasteur (Ph.D).
Former CFO of Halozyme Therapeutics, Inc. (NASDAQ:HALO); former VP and CFO of Lathian Health, Inc.; former VP, Treasurer and Director, Corporate Finance, at ICN Pharmaceuticals, Inc. (now Valeant Pharmaceuticals International, Inc.).
Chairman and CEO of Andrew-Technologies; former VP, BOTOX Global Strategic Marketing and Commercial Lead for Latisse at Allergan, responsible for driving the highly successful April 2002 launch of BOTOX Cosmetic; Former VP, North America Marketing for Nobel Biocare; Former President of Topical Aesthetic Division of Syneron Medical; Held marketing leadership roles at Parke-Davis to include 1997 launch of Lipitor.
Chief Technical Operations Officer and SVP at Ultragenyx (NASDAQ:RARE); former SVP of Manufacturing and Supply Chain at Intermune, Inc.; former VP of Biologics Manufacturing and Development at Allergan, Inc.